完整肿瘤包膜是经典型甲状腺乳头状癌预后良好的预测因素
该研究分析了554例经典型甲状腺乳头状癌(CVPTC)和600例滤泡型(FVPTC),按包膜完整性分组比较预后。结果显示有完整包膜的非侵袭性CVPTC(En-CVPTC)临床病理行为良好,与En-FVPTC相当,且BRAF V600E突变率更高(44.9% vs 7.7%,P<.0001)。提示完整包膜在CVPTC中同样具有良好预后价值。
要点
- En-CVPTC预后良好,与En-FVPTC相当。
- En-CVPTC的BRAF V600E突变率显著高于En-FVPTC。
- 完整包膜在CVPTC中也是良好预后的标志。
核心结论
- En-CVPTC虽较En-FVPTC少见,但具有与En-FVPTC相当的良好临床病理行为。
- 完整肿瘤包膜在CVPTC中同样具有良好预后预测作用。
- 可考虑为En-CVPTC引入类似NIFTP的新命名。
研究设计与样本
- 回顾性分析554例CVPTC和600例FVPTC病例。
- 根据包膜完整性分为包膜完整非侵袭性(En)和包膜侵袭性(Ei)及无包膜侵袭性(I)亚组。
- 对每个变异亚组评估BRAF突变。
主要发现
- E-FVPTC比E-CVPTC更常见(P < .001)。
- En-FVPTC与En-CVPTC之间、Ei-FVPTC与Ei-CVPTC之间未发现差异。
- 随访18年后,Ei-CVPTC未治愈病例数多于Ei-FVPTC,但En-CVPTC与En-FVPTC之间无此差异。
- 多变量聚类分析显示En-FVPTC、En-CVPTC和Ei-FVPTC特征相似,但与I-FVPTC、I-CVPTC及Ei-CVPTC不同。
- 614例中177例(28.8%)为BRAF V600E突变,10例(1.6%)携带BRAF罕见变异;En-CVPTC的BRAF V600E突变率(22/49,44.9%)显著高于En-FVPTC(15/195,7.7%)(P < .0001)。
关键数值与推荐
- En-CVPTC的BRAF V600E突变率为44.9%(22/49),En-FVPTC为7.7%(15/195),差异P < .0001。
- E-FVPTC与E-CVPTC的频数差异P < .001。
- 随访时间18年。
临床怎么用
- 对于包膜完整的CVPTC,可参考En-FVPTC进行预后评估和管理。
- 完整包膜可作为CVPTC良好预后的病理指标。
- BRAF V600E突变在En-CVPTC中常见,但预后仍良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Tumor capsule integrity is becoming a relevant issue to predict the biological behavior of human tumors, including thyroid cancer. OBJECTIVE: This work aims to verify whether a whole tumor capsule in the classical variant of papillary thyroid carcinoma (CVPTC) could have as a predictive role of a good outcome as for follicular variant (FVPTC). METHODS: FVPTC (n = 600) and CVPTC (n = 554) cases were analyzed. We distinguished between encapsulated-FVPTC (E-FVPTC) and encapsulated-CVPTC (E-CVPTC) and, thereafter, invasive (Ei-FVPTC and Ei-CVPTC) and noninvasive (En-FVPTC and En-CVPTC) tumors, according to the invasion or integrity of the tumor capsule, respectively. Cases without a tumor capsule were indicated as invasive-FVPTC (I-FVPTC) and invasive-CVPTC (I-CVPTC). The subgroup of each variant was evaluated for BRAF mutations. RESULTS: E-FVPTC was more frequent than E-CVPTC (P < .001). No differences were found between En-FVPTC and En-CVPTC or between Ei-FVPTC and Ei-CVPTC. After 18 years of follow-up, a greater number of not-cured cases were observed in Ei-CVPTC with respect to Ei-FVPTC, but not in En-CVPTC to En-FVPTC. Multivariate clustering analysis showed that En-FVPTC, En-CVPTC, and Ei-FVPTC have similar features but different from I-FVPTC and I-CVPTC and, to a lesser extent, from Ei-CVPTC. A total of 177 of 614 (28.8%) cases were BRAFV600E mutated, and 10 of 614 (1.6%) carried BRAF-rare alterations. A significantly higher rate of En-CVPTC (22/49, 44.9%) than En-FVPTC (15/195, 7.7%) (P < .0001) were BRAFV600E mutated. CONCLUSION: En-CVPTC is less prevalent than En-FVPTC. However, it has good clinical/ pathological behavior comparable to En-FVPTC. This finding confirms the good prognostic role of a whole tumor capsule in CVPTC as well. New nomenclature for En-CVPTC, similar to that introduced for En-FVPTC (ie, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; NIFTP) could be envisaged.
引用
- Giani C, Torregrossa L, Ramone T, et al. Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2021. PMID: 34231847. doi:10.1210/clinem/dgab396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。